Global Anticoagulant Reversal Drugs Market size to reach USD 1.6 Billion by 2027 - KBV Research
By: KBV Research
The andexanet alfa segment would exhibit promising CAGR over the forecast period owing to the increasing approval and launch of andexanet alfa in the major markets. The Centers for Medicare & Medicaid Services (CMS) in April 2020 established a J-code for Andexxa, thereby streamlining its reimbursement policies in the hospital outpatient settings. Therefore, supportive reimbursement policies for andexanet alfa in key markets would drive the segment growth throughout the forecast period.
The global anticoagulant reversal drugs market was dominated by Hospital pharmacy segment in 2020. As hospitals are the main centers where diagnosis and treatment of various types of bleeding disorders are performed, thus this segment is expected to grow significantly over the forecast period. Unstoppable bleeding due to blood-related disorders during emergency conditions will further drive the growth of the segment.
Full Report: https://www.kbvresearch.com/
Global Anticoagulant Reversal Drugs Market Segmentation
By Distribution Channel
By Product Type
+1 (646) 661-6066